Dear Doctor Letter (Rote-Hand-Brief) on Cipralex® (escitalopram): Risk of dose-dependent QT interval prolongation and altered recommendations as to the maximum dose in patients older than 65 years
2011.12.05
Active substance: escitalopram
Important information on the risk of dose-dependent prolongations of the QT interval as well as on altered recommendations as to the maximum dose in patients over 65 years of age. These new scientific findings also apply to all generic marketing authorisations of escitalopram. For these generics the BfArM has also initiated implementation of corresponding changes.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN